Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 8/20 | 0.48 |
| ▸ | CPT1A | P50416 | 8/20 | 0.48 |
| ▸ | CPT1B | Q92523 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353713 | 0.91 | MAPT (0.55) | MAPTLMNATP53PPARGPPARD | |
| SCHEMBL6351726 | 0.82 | MAPT (0.50) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL6357406 | 0.82 | CPT1A (0.54) | CPT2CPT1ACPT1BMAPTTP53 | |
| SCHEMBL6353169 | 0.82 | CPT1A (0.53) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL6830627 | 0.82 | CPT1A (0.46) | CPT2CPT1ACPT1BPPARGPPARD | |
| SCHEMBL6359987 | 0.80 | PPARG (0.65) | CPT2CPT1ACPT1BMAPTLMNA | |
| SCHEMBL6814072 | 0.79 | PPARG (0.49) | CPT2CPT1ACPT1BPPARGPPARD | |
| SCHEMBL6352881 | 0.76 | MAPT (0.56) | CPT2CPT1ACPT1BMAPTTP53 | |
| SCHEMBL15788196 | 0.75 | MAPT (0.61) | MAPTTP53PPARGPPARDPPARA | |
| SCHEMBL6360706 | 0.73 | RPA1 (0.50) | MAPTTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | CPT2 3152/4885CPT1A 4114/4885CPT1B 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.